Larotrectinib sulfate is under clinical development by Bayer and currently in Phase II for Non-Hodgkin Lymphoma. According to GlobalData, Phase II drugs for Non-Hodgkin Lymphoma have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Larotrectinib sulfate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Larotrectinib sulfate overview
Larotrectinib Sulfate (Vitrakvi) is a anti-neoplastic agent. It is formulated as solution and hard gelatin capsules for oral route of administration. Vitrakvi is indicated for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation are metastatic or where surgical resection is likely to result in severe morbidity, have no satisfactory alternative treatments or that have progressed following treatment, neurotrophic receptor tyrosine kinase (NTRK) fusion gene positive advanced or recurrent.
Larotrectinib (LOXO-101) is under development for the treatment of solid tumors such as pancreatic cancer, colon cancer, non-small cell lung cancer, soft tissue sarcoma, thyroid cancer, colorectal cancer, salivary gland cancer, biliary tumor, melanoma, bile duct cancer (Cholangiocarcinoma), secretory breast cancer, non-Hodgkin lymphomas, Langerhans cell histiocytosis (LCH), juvenile xanthogranuloma (JXG), histiocytic sarcoma, multiple myeloma, intrinsic brain stem tumors, optic pathway gliomas, pineal tumors, head and neck cancer squamous cell carcinoma, fibrosarcoma, gastrointestinal stromal tumor (GIST) including appendiceal cancer, pontine glioma, pancreatic cancer, ovarian cancer, kidney cancer, astrocytoma,neuroblastoma and cancers with a NTRK1, NTRK2, or NTRK3 gene fusion. It is administered orally. It targets pan tropomyosin receptor kinases (TrkA, TrkB, and TrkC). The drug candidate is developed based on Array drug discovery platform.
Bayer is engaged in the discovery, development, manufacturing, and commercialization of products for human health, and agriculture. It provides medicines for cardiovascular diseases, women’s health, cancer, hematology, ophthalmology, and other indications. It also strives to develop new molecules and technologies for use in the fields of medicine and modern agriculture. The company’s product portfolio includes prescription products, specialty pharmaceuticals, diagnostic imaging equipment, non-prescription (over the counter or OTC) products, seeds, crop protection solutions and non-agricultural pest control solutions. Bayer markets its healthcare and crop protection products essentially through wholesalers, pharmacies, hospitals, and retailers. It operates through a network of subsidiaries in Asia-Pacific, Europe, North America, Latin America, Africa, and the Middle East. Bayer is headquartered in Leverkusen, North Rhine-Westphalia, Germany.
For a complete picture of Larotrectinib sulfate’s drug-specific PTSR and LoA scores, buy the report here.